AcuCort AB (publ) (NGM: ACUC)

Market Cap	97.72M
Revenue (ttm)	6.99M
Net Income (ttm)	-14.86M
Shares Out	119.17M
EPS (ttm)	-0.26
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	82,273
Open	0.846
Previous Close	0.844
Day's Range	0.800 - 0.848
52-Week Range	0.342 - 1.260
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 21, 2024

About AcuCort AB

AcuCort AB (publ) develops and commercializes glucocorticoid dexamethasone films for the treatment of acute allergic conditions. It offers Zeqmelit, a medicine used for the treatment of severe and acute allergic reactions, croup in children, and chemotherapy-induced nausea and vomiting, as well as for the treatment of COVID-19 patients who need supplemental oxygen treatment. AcuCort AB (publ) was incorporated in 2006 and is based in Lund, Sweden.

• Industry: Pharmaceutical Preparations
• Founded: 2006
• Employees: 3
• Stock Exchange: Nordic Growth Market
• Ticker Symbol: ACUC

Financial Performance

In 2023, AcuCort AB's revenue was 6.59 million, an increase of 31.24% compared to the previous year's 5.02 million. Losses were -13.69 million, -7.42% less than in 2022.